Table 2.

Virological outcomes for patients who reached the pre-defined time points

Parameter	EOT	EOT+12 weeks	EOT+24 weeks	EOT+12 or EOT+24 weeks combined
Number of patients evaluated at the time point, N	127	83	77	105
In follow-up at the time point, n	0	22	50	22
Lost to follow-up, n	1*	1*	2*#	1*
Missed visit, n	1	22§	0	0
Patients with available HCV RNA data, n	125	82	75	104
HCV RNA target detected, quantifiable, n	0	1	1	1
HCV RNA target detected, below LLD, n	1	0	0	0
HCV RNA target not detected, n/N (%)	124	81	74	103
Virological response rate, ITT, n/N (%)	125/127 (98.4)	81/83 (97.6)	74/77 (96.1)	103/105 (98.1)
Virological response rate, mITT, n/N (%)	125/125 (100.0)	81/82 (98.8)	74/75 (98.7)	103/104 (99.0)

^*One patient died due to myocardial infarction while on therapy; not included in modified ITT analysis.

^#One patient who reached SVR12 died due to recurrent hepatocellular carcinoma and deterioration of liver disease before EOT+24 weeks time point; not included in modified ITT SVR24 analysis.

^§HCV RNA testing at EOT+12 weeks time point is not mandatory in Hungary.

N – total number of patients, n – number of patients, EOT – end of treatment, HCV – hepatitis C virus, RNA – ribonucleic acid, LLD – lower limit of detection, ITT – intent to treat, mITT – modified intent to treat, SVR – sustained virological response